Nicholas James Leeper, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Leeper’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A90602 · Current
Licensed to practise in California · since 2005 · expires 2028-12-31 · University of Chicago, Pritzker School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Medicaid work
$4,495 in 2023
Medicaid paid $4,495 for 182 billed services this clinician did in 2023, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| EXTREMITY STUDY | 69 | $2,210 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 46 | $1,581 |
| LOWER EXTREMITY STUDY | 18 | $284 |
| Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels) | 37 | $263 |
| Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia) | 12 | $156 |
| 2023 | 182 | 5 | 19 | $4,495 |
| 2022 | 41 | 2 | 15 | $937 |
| 2021 | 40 | 3 | 14 | $663 |
| 2020 | 130 | 3 | 61 | $1,685 |
| 2019 | 75 | 1 | 70 | $721 |
| 2018 | 47 | 2 | 15 | $845 |
See the largest Medicaid services in earlier years
2022
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 27 | $790 |
| Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels) | 14 | $147 |
2021
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 14 | $275 |
| EXTREMITY STUDY | 13 | $269 |
| Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels) | 13 | $119 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 105 | $1,159 |
| EXTREMITY STUDY | 12 | $388 |
| Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels) | 13 | $139 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 75 | $721 |
2018
| Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels) | 35 | $431 |
| EXTREMITY STUDY | 12 | $414 |
Drugs they prescribed that Part D paid
$72,804
Pharmacies billed $72,804 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 265) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
205 generic and 60 brand-name prescriptions · $72,804 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Repatha Sureclick | 37 | $44,658 | $1,207 |
| Xarelto | 19 | $19,375 | $1,020 |
| Rosuvastatin | 38 | $574 | $15 |
| Ezetimibe | 30 | $556 | $19 |
| Amlodipine Besylate | 29 | $312 | $11 |
See all 8 drugs
| Repatha Sureclick | 37 | $44,658 | $1,207 |
| Xarelto | 19 | $19,375 | $1,020 |
| Rosuvastatin | 38 | $574 | $15 |
| Ezetimibe | 30 | $556 | $19 |
| Amlodipine Besylate | 29 | $312 | $11 |
| Atorvastatin | 24 | $264 | $11 |
| Carvedilol | 22 | $230 | $10 |
| Losartan | 14 | $199 | $14 |
Year by year
| 2024 | 265 | 40 | 0% (0) | 23% | $72,804 |
| 2023 | 437 | 53 | 0% (0) | 19% | $88,898 |
| 2022 | 430 | 47 | 0% (0) | 21% | $66,962 |
| 2021 | 395 | 44 | 0% (0) | 23% | $52,547 |
| 2020 | 242 | 44 | 0% (0) | 14% | $26,558 |
| 2019 | 293 | 53 | 0% (0) | 18% | $30,703 |
| 2018 | 287 | 48 | 0% (0) | 7% | $15,309 |
| 2017 | 292 | 40 | 0% (0) | 11% | $16,940 |
| 2016 | 365 | 46 | 0% (0) | 11% | $19,253 |
| 2015 | 316 | 50 | 0% (0) | 16% | $16,245 |
| 2014 | 321 | 42 | 0% (0) | 17% | $12,179 |
| 2013 | 251 | 37 | None | 25% | $9,268 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Repatha Sureclick | 51 | $53,200 | $1,043 |
| Xarelto | 16 | $12,817 | $801 |
| Ezetimibe | 60 | $4,481 | $75 |
| Vascepa | 13 | $3,449 | $265 |
| Rosuvastatin | 51 | $953 | $19 |
| Atorvastatin | 44 | $936 | $21 |
| Amlodipine Besylate | 46 | $513 | $11 |
| Carvedilol | 32 | $451 | $14 |
| Losartan | 19 | $238 | $13 |
2022: 8 drugs
| Repatha Sureclick | 52 | $34,640 | $666 |
| Xarelto | 29 | $15,919 | $549 |
| Ezetimibe | 59 | $3,262 | $55 |
| Rosuvastatin | 51 | $942 | $18 |
| Atorvastatin | 44 | $833 | $19 |
| Carvedilol | 35 | $532 | $15 |
| Amlodipine Besylate | 38 | $173 | $5 |
| Metoprolol | 16 | $142 | $9 |
2021: 10 drugs
| Repatha Sureclick | 34 | $20,802 | $612 |
| Xarelto | 22 | $13,166 | $598 |
| Vascepa | 17 | $3,444 | $203 |
| Ezetimibe | 62 | $2,518 | $41 |
| Rosuvastatin | 28 | $1,194 | $43 |
| Atorvastatin | 41 | $653 | $16 |
| Carvedilol | 28 | $212 | $8 |
| Amlodipine Besylate | 32 | $142 | $4 |
| Metoprolol | 15 | $41 | $3 |
| Lisinopril | 17 | $30 | $2 |
2020: 7 drugs
| Xarelto | 15 | $11,624 | $775 |
| Ezetimibe | 55 | $3,077 | $56 |
| Vascepa | 12 | $3,029 | $252 |
| Atorvastatin | 44 | $966 | $22 |
| Rosuvastatin | 17 | $163 | $10 |
| Amlodipine Besylate | 16 | $83 | $5 |
| Metoprolol | 14 | $36 | $3 |
2019: 8 drugs
| Xarelto | 28 | $16,635 | $594 |
| Ezetimibe | 58 | $3,894 | $67 |
| Atorvastatin | 58 | $1,117 | $19 |
| Losartan | 12 | $197 | $16 |
| Clopidogrel | 13 | $96 | $7 |
| Amlodipine Besylate | 20 | $93 | $5 |
| Metoprolol | 16 | $91 | $6 |
| Hydrochlorothiazide | 19 | $48 | $3 |
2018: 10 drugs
| Ezetimibe | 27 | $2,223 | $82 |
| Atorvastatin | 50 | $1,694 | $34 |
| Rosuvastatin | 11 | $1,084 | $99 |
| Cilostazol | 21 | $268 | $13 |
| Amlodipine Besylate | 29 | $223 | $8 |
| Losartan | 11 | $128 | $12 |
| Metoprolol | 18 | $96 | $5 |
| Lisinopril | 12 | $39 | $3 |
| Hydrochlorothiazide | 13 | $28 | $2 |
| Carvedilol | 11 | $21 | $2 |
2017: 8 drugs
| Atorvastatin | 73 | $1,800 | $25 |
| Rosuvastatin | 13 | $807 | $62 |
| Cilostazol | 21 | $332 | $16 |
| Amlodipine Besylate | 24 | $203 | $8 |
| Metoprolol | 40 | $150 | $4 |
| Lisinopril | 19 | $83 | $4 |
| Carvedilol | 13 | $29 | $2 |
| Simvastatin | 12 | $28 | $2 |
2016: 9 drugs
| Crestor | 13 | $5,207 | $401 |
| Atorvastatin | 99 | $1,894 | $19 |
| Cilostazol | 15 | $382 | $25 |
| Nifedipine Er | 11 | $191 | $17 |
| Lisinopril | 33 | $171 | $5 |
| Metoprolol | 42 | $160 | $4 |
| Hydrochlorothiazide | 24 | $142 | $6 |
| Amlodipine Besylate | 14 | $78 | $6 |
| Simvastatin | 15 | $41 | $3 |
2015: 9 drugs
| Crestor | 27 | $7,764 | $288 |
| Atorvastatin | 79 | $1,264 | $16 |
| Valsartan | 12 | $1,186 | $99 |
| Clopidogrel | 14 | $212 | $15 |
| Pravastatin | 13 | $194 | $15 |
| Amlodipine Besylate | 36 | $137 | $4 |
| Lisinopril | 29 | $115 | $4 |
| Metoprolol | 20 | $78 | $4 |
| Hydrochlorothiazide | 16 | $40 | $3 |
2014: 9 drugs
| Crestor | 24 | $6,373 | $266 |
| Atorvastatin | 60 | $791 | $13 |
| Clopidogrel | 22 | $518 | $24 |
| Pravastatin | 27 | $496 | $18 |
| Amlodipine Besylate | 34 | $280 | $8 |
| Lisinopril | 45 | $236 | $5 |
| Isosorbide Mononitrate Er | 12 | $157 | $13 |
| Carvedilol | 22 | $156 | $7 |
| Metoprolol | 19 | $109 | $6 |
2013: 8 drugs
| Crestor | 17 | $3,300 | $194 |
| Atorvastatin | 38 | $777 | $20 |
| Clopidogrel | 21 | $460 | $22 |
| Amlodipine Besylate | 37 | $235 | $6 |
| Carvedilol | 19 | $179 | $9 |
| Pravastatin | 13 | $151 | $12 |
| Lisinopril | 22 | $126 | $6 |
| Metoprolol | 11 | $51 | $5 |
Money from drug and device companies
$1,074 in 2023
| 2023 | 1 | 2 | $1,074 | $1,074 |
| 2020 | 3 | 13 | $14,094 | $15,065 |
| 2019 | 2 | 5 | $18,542 | $18,542 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Pharmaceuticals | None | $1,074 | 2 payments
|
See all 2 published payments
| Regeneron Pharmaceuticals | Consulting · 2023-09-22 | None | $716 |
| Regeneron Pharmaceuticals | Consulting · 2023-09-22 | None | $358 |
See earlier years (2020, 2019)
2020: $15,065
| Janssen Pharmaceuticals | Xarelto | $5,611 | 8 payments
|
| Sanofi US Services | None | $4,854 | 2 payments
|
| Janssen Scientific Affairs | Xarelto | $4,600 | 3 payments
|
2019: $18,542
| Sanofi US Services | None | $12,742 | 1 payment
|
| Janssen Scientific Affairs | Xarelto | $5,800 | 4 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Bayer HealthCare Pharmaceuticals Inc. · Bay59-7939 2.5mg Reduction Atherothrombotic Events Vs. Asa · 2020 | Their institution | $48,045 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay59-7939 2.5mg Reduction Atherothrombotic Events Vs. Asa · 2019 | Their institution | $26,781 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407044639
- Licence
- CA A90602California A90602: Current · expires 2028-12-31
- Trained
- University of Chicago, Pritzker School of Medicine, 2003
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2007-10-12
- NPI last updated
- 2024-04-23
- NPI record certified
- 2024-04-23
This is when the NPI record was last certified, not a medical board exam.